TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rocket Pharmaceuticals ( (RCKT) ) has issued an announcement.
On June 18, 2025, Rocket Pharmaceuticals held its Annual Meeting of Stockholders, where 85.56% of the total outstanding shares were represented. During the meeting, stockholders approved the election of ten directors, ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for 2025, and supported the compensation of the company’s named executive officers.
The most recent analyst rating on (RCKT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing gene therapies for rare and devastating diseases.
Average Trading Volume: 4,891,117
Technical Sentiment Signal: Sell
Current Market Cap: $310.3M
For an in-depth examination of RCKT stock, go to TipRanks’ Overview page.